MedPath

Phase III Trial of Stage I Ovarian Cancer After Surgery

Phase 3
Recruiting
Conditions
Epithelial Ovarian Cancer
Interventions
Drug: adjuvant chemotherapy
Registration Number
NCT04063527
Lead Sponsor
Japanese Gynecologic Oncology Group
Brief Summary

To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery

Detailed Description

Based on the following adjustment factors, patients will be randomly assigned in a 1:1 ratio to adjuvant chemotherapy or observation groups.

1. Histologic type: clear cell adenocarcinoma/mucinous adenocarcinoma vs. serous adenocarcinoma/other histologic types

2. Facility where a subject is enrolled

3. International Federation of Gynecology and Obstetrics(FIGO) clinical staging: Stage Ia/ Ib vs. Stage Ic(b)

Group A: adjuvant chemotherapy group (standard treatment group):

While one of the following treatments will be performed, the number of cycles is entrusted to the treatment policy of each facility.

Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles Docetaxel plus Carboplatin (DC) therapy; Docetaxel(DTX) 70 mg/m2 + CBDCA AUC 6 q3weeks day1, 3 to 6 cycles

After the start of TC therapy, switching from PTX to DTX due to an adverse event is permitted.

Group B: observation group (study treatment group): Observation only, no adjuvant chemotherapy administered.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
360
Inclusion Criteria
  1. Patients with a diagnosis of histopathologically epithelial ovarian cancer

  2. FIGO Stages Ia(Grade2/3, clear cell carcinoma), Ib(Grade2/3, clear cell carcinoma) and Ic(b)(all degree of differentiation and all histologic type)

  3. Patients with a diagnosis of advanced stage by comprehensive staging or restaging laparotomy.

  4. Patients who received comprehensive staging surgery (basic surgical techniques (total hysterectomy, bilateral salpingo-oophorectomy, and omentectomy) as well as peritoneal cytology, multiple biopsies of the peritoneum ([Peritoneal biopsy] see details below), retroperitoneal lymph node dissection (see details below [Retroperitoneal lymph node dissection]).

    However, for the following cases, it is eligible as a condition to record on the official document.

    • Peritoneal biopsy: peritoneal metastasis is not recognized by macroscopic and palpation in the stipulated site, and the case that biopsy has not been performed.
    • Retroperitoneal lymph node dissection: the case that lymph nodes of the stipulated range has been dissected however the prescribed number has not been reached.
  5. Age: 20 or older

  6. Performance status (PS):0-1

  7. Case with initial therapy for postoperative primary lesion

  8. Patient possible to receive the first study treatment within 8 weeks after the comprehensive staging surgery

  9. Reasonable organ function

  10. Patient must have signed informed consent.

Exclusion Criteria
  1. FIGO Stages Ic(a), Ic(1) and Ic(2)
  2. Patients containing sarcoma elements
  3. Patients with any signs of interstitial pneumonia or pulmonary fibrosis by chest radiography and CT
  4. Patients with serious complications
  5. Patients with active infection
  6. Patients with intestinal paralysis or intestinal obstruction
  7. Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy
  8. Patients with previous chemotherapy or radiation therapy
  9. Patients with serious drug hypersensitivity
  10. Patients with peripheral motor/sensory neuropathy [grade2,3,4 Common Terminology Criteria for Adverse Events (CTCAE) 4.0]
  11. Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil
  12. Patients with positive HBsAg. Patients with more than 2.1 log/copies ml based on fixed Hepatitis B virus (HBV)-DNA who are positive with either antigen-positive Hepatitis B (HBs), anti-hepatitis B core antigen or anti-hepatitis B surface antigen.
  13. Patients who are inappropriate to enter this study with any safety reasons, judged by the treating physician

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard therapyadjuvant chemotherapycombination of paclitaxel and carboplatin
Primary Outcome Measures
NameTimeMethod
Overall survivalFrom date of randomization until the date of death from any cause, assessed up to 60 months

1. In surviving patients, cut off will be on the last date the patient is confirmed to be alive.

2. If a patient is lost to follow-up, cut off will be on the last date the patient is confirmed to be alive before being lost to follow-up.

Secondary Outcome Measures
NameTimeMethod
Relapse-free survivalFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

1. If relapse is diagnosed through imaging, it is considered an event on the "test date" on which a "definite diagnosis" is obtained and not the test date that showed a "suspected relapse on an image." If a relapse is clinically diagnosed, not just through imaging, it is considered an event on the date on which relapse is diagnosed.

2. Progression observed by CA-125 only shall not be handled as an event in this study.

Trial Locations

Locations (103)

Tokyo Metropolitan Tama Medical Center

🇯🇵

Fuchu-shi, Tokyo, Japan

Sasaki Faundation Kyoundo Hospital

🇯🇵

Chiyoda, Tokyo, Japan

Tokyo Medical And Dental University University Hospital of Medicine

🇯🇵

Bunkyō-Ku, Tokyo, Japan

Keio University Hospital

🇯🇵

Shinjuku-ku, Tokyo, Japan

Tokyo Women's Medical University Hospital

🇯🇵

Shinjuku-Ku, Tokyo, Japan

The Cancer Institute Hospital

🇯🇵

Koto-Ku, Tokyo, Japan

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

🇯🇵

Bunkyō-Ku, Tokyo, Japan

Toho University Ohashi Medical Center

🇯🇵

Meguro-ku, Tokyo, Japan

Tokyo Women's Medical University Medical Center East

🇯🇵

Arakawa, Tokyo, Japan

The University of Tokyo Hospital

🇯🇵

Bunkyō-Ku, Tokyo, Japan

Tottori Prefectural Central Hospital

🇯🇵

Tottori-shi, Tottori, Japan

The Jikei University Hospital

🇯🇵

Minato-ku, Tokyo, Japan

Kosei General Hospital

🇯🇵

Suginami, Tokyo, Japan

Tokuyama Central Hospital

🇯🇵

Shunan-shi, Yamaguchi, Japan

Tachikawa Hospital

🇯🇵

Tachikawa-shi, Tokyo, Japan

Kangbuk Samsung Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul ST' Mary's Hospital

🇰🇷

Seocho, Seoul, Korea, Republic of

Saiseikai Nagasaki Hospital

🇯🇵

Nagasaki, Japan

National Cancer Center

🇰🇷

Ilsandong, Goyang, Korea, Republic of

Gifu University Hospital

🇯🇵

Gifu-shi, Gifu, Japan

Hirosaki University School of Medicine & Hospital

🇯🇵

Hirosaki-shi, Aomori, Japan

Kyusyu Cancer Center

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Gunma Prefectural Cancer Center

🇯🇵

Ōta, Gunma, Japan

Hospital Hakodate Hokkaido

🇯🇵

Hakodate-shi, Hokkaido, Japan

Miyoshi Central Hospital

🇯🇵

Miyoshi-shi, Hiroshima, Japan

University of Tsukuba Hospital

🇯🇵

Tsukuba-shi, Ibaraki, Japan

Tokai University Hospital

🇯🇵

Isehara-shi, Kanagawa, Japan

JA Matsuzaka Central Hospital

🇯🇵

Matsuzaka, Mie, Japan

Kumamoto University Hospital

🇯🇵

Kumamoto-shi, Kumamoto, Japan

Nara Prefecture General Medical Center

🇯🇵

Nara-shi, Nara, Japan

Osaka Medical College Hospital

🇯🇵

Takatsuki-shi, Osaka, Japan

Osaka International Cancer Center

🇯🇵

Osaka-shi, Osaka, Japan

Dokkyo Medical University Saitama Medical Center

🇯🇵

Koshigaya-shi, Saitama, Japan

Okinawa Prefectural Chubu Hospital

🇯🇵

Uruma-shi, Okinawa, Japan

Shimane University Hospital

🇯🇵

Izumo, Shimane, Japan

National Cancer Center Hospital East

🇯🇵

Kashiwa-shi, Chiba, Japan

Kyushu University Hospital

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Kurume University Hospital

🇯🇵

Kurume-shi, Fukuoka, Japan

Gunma University Hospital

🇯🇵

Maebashi, Gunma, Japan

JA Sapporo-Kosei general Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

Hokkaido University Hospita

🇯🇵

Sapporo-shi, Hokkaido, Japan

Kansai Rosai Hospital

🇯🇵

Amagasaki-shi, Hyogo, Japan

Japanese Red Cross Society Himeji Hospital

🇯🇵

Himeji-shi, Hyogo, Japan

Kagoshima City Hospital

🇯🇵

Kagoshima-shi, Kagoshima, Japan

Iwate Medical University Hospital

🇯🇵

Morioka-shi, Iwate, Japan

Yokohama Municipal Citizen's Hospital

🇯🇵

Yokohama-shi, Kanagawa, Japan

Kitasato University Hospital

🇯🇵

Sagamihara, Kanagawa, Japan

Kobe City Medical Center General Hospital

🇯🇵

Kobe-shi, Kobe, Japan

Japanese Red Cross Kyoto Daiichi Hospital

🇯🇵

KYoto-shi, Kyoto, Japan

Tohoku University Hospital

🇯🇵

Sendai-shi, Miyagi, Japan

Niigata University Medical and Dental Hospital

🇯🇵

Niigata-shi, Niigata, Japan

Hospital University of the Ryukyus

🇯🇵

Nakagami-gun, Okinawa, Japan

Niigata Cancer Center Hospital

🇯🇵

Niigata-shi, Niigata, Japan

Tomishiro Central Hospital

🇯🇵

Tomishiro-shi, Okinawa, Japan

Kaizuka City Hospital

🇯🇵

Kaizuka, Osaka, Japan

Sakai City Medical Center

🇯🇵

Sakai, Osaka, Japan

Osaka University Hospital

🇯🇵

Suita-shi, Osaka, Japan

Dokkyo Medical University Hospital

🇯🇵

Mibu, Tochgi, Japan

Jichi Medical University Hospital

🇯🇵

Shimotsuke-shi, Tochigi, Japan

Tokushima University Hospital

🇯🇵

Tokushima-shi, Tokushima, Japan

Yamagata University Hospital

🇯🇵

Yamagata-shi, Yamagata, Japan

Tottori University Hospital

🇯🇵

Yonago-shi, Tottori, Japan

Yamaguchi Red Cross Hospital

🇯🇵

Yamaguchi-shi, Yamaguchi, Japan

Nagano Municipal Hospital

🇯🇵

Nagano, Japan

Saga University Hospital

🇯🇵

Saga, Japan

Jichi Medical University Saitama Medical Center

🇯🇵

Saitama, Japan

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

The Jikei University School of Medicine Kashiwa Hospital

🇯🇵

Kashiwa-shi, Chiba, Japan

Kyusyu Medical Center

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Ehime University Hospital

🇯🇵

Onsen-gun, Ehime, Japan

JA Hiroshima General Hospital

🇯🇵

Hatsukaichi-shi, Hiroshima, Japan

Hiroshima City Hiroshima Citizens Hospital

🇯🇵

Hiroshima-shi, Hiroshima, Japan

Hyogo Cancer Center

🇯🇵

Akashi-shi, Hyogo, Japan

Hiroshima Prefectural Hospital

🇯🇵

Hiroshima-shi, Hiroshima, Japan

St.Marianna University School of Medicine Hospital

🇯🇵

Kawasaki-shi, Kanagawa, Japan

Kagoshima University Medical And Dental Hospital

🇯🇵

Kagoshima-shi, Kagoshima, Japan

Yokohama Minami Kyosai Hospital

🇯🇵

Yokohama, Kanagawa, Japan

Kanagawa Cancer Center

🇯🇵

Yokohama, Kanagawa, Japan

Nagasaki University Hospital

🇯🇵

Nagasaki-shi, Nagasaki, Japan

Shinshu University Hospital

🇯🇵

Matsumoto-shi, Nagano, Japan

Aichi Cancer Center

🇯🇵

Nagoya-shi, Nagoya, Japan

Oita University Hospital

🇯🇵

Yufu, Oita, Japan

Osaka City University Hospital

🇯🇵

Osaka-shi, Osaka, Japan

Koshigaya Municipal Hospital

🇯🇵

Koshigaya-shi, Saitama, Japan

Saitama Cancer Center

🇯🇵

Ina, Saitama, Japan

Kindai University Hospital

🇯🇵

Ōsaka-sayama-shi, Osaka, Japan

Saitama National Hospital

🇯🇵

Wako, Saitama, Japan

Shizuoka Cancer Center

🇯🇵

Nagaizumi-chō, Shizuoka, Japan

Nippon Medical School Hospital

🇯🇵

Bunkyō-Ku, Tokyo, Japan

The Jikei University Katsushika Medical Center

🇯🇵

Katsushika-ku, Tokyo, Japan

The Jikei University Daisan Hospital

🇯🇵

Komae-shi, Tokyo, Japan

Gachon University Gil Medical Center

🇰🇷

Namdong, Incheon, Korea, Republic of

Tosei General Hospital

🇯🇵

Seto-shi, Aichi, Japan

Ise Red Cross Hospital

🇯🇵

Ise-shi, Mie, Japan

Mie University Hospital

🇯🇵

Tsu, Mie, Japan

Shikoku Cancer Center

🇯🇵

Matsuyama-shi, Shikoku, Japan

Aichi Medical University Hospital

🇯🇵

Nagakute-shi, Aichi, Japan

National Defense Medical College Hospital

🇯🇵

Tokorozawa-shi, Saitama, Japan

Fujita Health University Hospital

🇯🇵

Toyoake-shi, Aichi, Japan

Saitama Medical University International Medical Center

🇯🇵

Hidaka-shi, Saitama, Japan

Yokohama City University Hospital

🇯🇵

Yokohama, Kanagawa, Japan

Sapporo Medical University Hospital

🇯🇵

Sapporo-shi, Sapporo, Japan

Japanese Red Cross Shizuoka Hospital

🇯🇵

Shizuoka-shi, Shizuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath